Author: NervGen Pharma Corp.

Posted Date:

April 27, 2026

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

NervGen Pharma Corp.

April 27, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Corp.

April 13, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Corp.

April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

NervGen Pharma Corp.

April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

NervGen Pharma Corp.

March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

NervGen Pharma Corp.

March 13, 2026
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

NervGen Pharma Corp.

March 4, 2026
NervGen Pharma to Participate at Upcoming Investor Conferences

NervGen Pharma Corp.

February 18, 2026
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

NervGen Pharma Corp.

February 17, 2026
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

NervGen Pharma Corp.

February 16, 2026